Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solana Company filings document a Delaware issuer with Nasdaq-listed Class A common stock and a business profile that includes a Solana (SOL) digital asset treasury following its history as Helius Medical Technologies. Recent 8-K reports cover operating results, staking-reward revenue, digital-asset fair value effects, capital actions, registered-direct equity financing, put-option arrangements, and outstanding common stock and pre-funded warrants.
Governance filings include director and officer changes, separation and employment arrangements, board composition, and definitive proxy materials for annual-meeting matters, executive compensation, equity awards, and shareholder voting items. The filings also describe the company’s expansion from its medical-device neurotechnology legacy into SOL holdings, staking, custody, and related infrastructure initiatives.
Summer Wisdom Holdings Ltd, a ten percent owner of Solana Co, reported an internal restructuring of its indirect holdings of Class A Common Stock. On May 11, 2026, an affiliate, Fusion Summer Limited, made a pro‑rata distribution-in-kind of 1,453,277 shares of Class A Common Stock to one of its members for no consideration. Following this transaction, Summer Wisdom is reported as beneficially owning 5,377,125 Class A Common shares indirectly through Fusion Summer.
Summer Wisdom Holdings Ltd, a more than ten percent owner of Solana Co, reports its initial beneficial ownership of the company’s securities. It indirectly holds 6,830,402 shares of Class A Common Stock through Fusion Summer Limited. It also holds Strategic Advisory Warrants directly, exercisable at $0.001 per share for 2,218,236 underlying Class A shares, subject to a 9.99% Beneficial Ownership Blocker, so these warrants are not currently exercisable. In addition, it indirectly holds Cash Stapled Warrants tied to 6,830,402 underlying Class A shares at an exercise price of $10.134 per share, expiring in 2028.
Solana Co director Jiang Cosmo Yi exercised warrants to acquire 1,005,040 shares of common stock. The warrants carried an exercise price of $0.001 per share and had become fully vested and immediately exercisable as of May 3, 2026, following an acceleration elected by Yi.
In connection with this cashless exercise, 610 shares were withheld by the company at $1.65 per share to satisfy obligations, so this portion is a tax-withholding disposition rather than an open-market sale. After these transactions, Yi directly holds 1,004,430 shares of Solana Co common stock.
Solana Co director Jiang Cosmo Yi received a warrant covering 1,005,040 shares of common stock. The warrant has an exercise price of $0.001 per share and expires on September 18, 2030. It vests 25% on March 18, 2026, with the remaining 75% vesting in equal monthly installments over 36 months, subject to continued service.
Solana Company amended and restated its at-the-market stock sales agreement with Clear Street LLC and Maxim Group LLC, increasing the maximum aggregate offering price of Class A common shares in the program from $92.8 million to $250 million. The company uses a shelf registration on Form S-3 and a new prospectus supplement to support these sales. As of May 29, 2026, it has previously sold shares for aggregate gross proceeds of $24,657,697.51 under the prior agreement and prospectus supplement, which will no longer be used. Sales, if any, will be made from time to time at the company’s discretion, with the agents earning up to 3.00% of gross proceeds and receiving reimbursement of certain legal expenses.
Solana Company is offering shares of Class A common stock having an aggregate offering price of up to $250,000,000 pursuant to an amended and restated sales agreement with Clear Street LLC and Maxim Group LLC dated May 29, 2026.
The offering may be made from time to time as an at‑the‑market (ATM) program or by negotiated transactions; sales agents may receive up to 3.0% of gross proceeds. The company intends to use net proceeds, together with existing cash, to accumulate SOL tokens, for working capital and general corporate purposes. The prospectus supplement states 177,510,127 shares would be outstanding after an illustrative sale based on an assumed price of $2.04 per share.
Solana Co director Sergio Mello reported equity compensation awards from the company. He received 6,360 shares of Class A Common Stock as restricted stock units granted at no cash cost, bringing his directly held common shares reported in this filing to 6,360.
He was also granted stock options for 18,564 shares of Class A Common Stock at an exercise price of $2.36 per share, with 18,564 derivative securities reported as held after the grant. Both the RSUs and options vest in twelve equal monthly installments over one year, conditioned on his continued service through each vesting date.
Solana Co director Lee Michel Kai Tai received new equity awards as part of compensation. He was granted 6,360 restricted stock units of Class A Common Stock and a stock option for 18,564 shares at an exercise price of $2.3600 per share.
The RSUs and options both vest in twelve equal monthly installments on the last day of each month, fully vesting one year after the grant date, subject to continued service. After these awards, he holds 6,360 Class A shares and 18,564 options directly.
Solana Co director Edward M. Straw reported equity awards in the company’s Class A Common Stock. He received 6,360 restricted stock units that vest in twelve equal monthly installments over one year, subject to continued service. He was also granted options on 18,564 shares at an exercise price of $2.36 per share, vesting monthly over the same one-year period and expiring in 2036. Following the RSU grant, his direct common stock holdings total 8,542 shares.
Solana Co director Walter Blane received new equity awards. He was granted 6,360 shares of Class A Common Stock in the form of restricted stock units and 18,564 stock options with an exercise price of $2.3600 per share.
The RSUs and options each vest in twelve equal monthly installments, fully vesting on the one-year anniversary of the May 21, 2026 grant date, subject to continued service. Following the RSU grant, Blane directly holds 8,542 Class A Common shares, and the options are exercisable into 18,564 shares until their expiration on May 20, 2036.